IMPDH inhibitors for anti-tumor therapy in tuberous sclerosis complex
A. J. Valvezan, S. K. Miller, M. C. McNamara, M. E. Torrence, J. M. Asara, E. P. Henske, B. D. Manning
This paper evaluates IMPDH inhibitors for anti-tumor therapy in TSC, finding mizoribine more effective than mycophenolic acid in targeting mTORC1-driven tumors.
bioRxiv · Nov 11, 2019Cancer Biology